OpenAlex
PricingAboutJobs
Log inGet started
Work

Ipilimumab: controversies in its development, utility and autoimmune adverse events

HTML

Year: 2009
Type: article
Source: Cancer Immunology Immunotherapy
DOI: 10.1007/s00262-008-0653-8
Author: Jeffrey Weber
Institutions: University of South Florida, Moffitt Cancer Center
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: ipilimumab, CTLA-4, immune checkpoint inhibitors, immune-related adverse events, melanoma, dose and schedule optimization, tumor microenvironment, immunosuppression, RECIST criteria, immune checkpoint blockade
SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, National Cancer Institute
OpenAlex ID: W2148576689
FWCI: 17.21
Cites: 36
Cited by: 234
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms